LIPID NANOPARTICLES FOR TARGETED siRNA DELIVERY

1 . A composition comprising a lipid nanoparticle which comprises a lipid bi-layer, and a lipid having a single-chain variable fragment (scFv) attached thereto via a hydrophilic polymer wherein the scFv is directed against an antigen present on the surface of a cell.

2 . The composition of claim 1 , comprising an ionizable cationic lipid.

3 . The composition of claim 1 , comprising distearoylphosphatidylcholine (DSPC).

4 . The composition of claim 2 , wherein the ionizable cationic lipid comprises 1,2-DiLinoleyloxy-N,N-dimethylaminopropane (DLinDMA).

5 . The composition of claim 1 , comprising one or more of 1,2-dilinoleyl-4-(2-dimethylaminoethyl)[1,3]-dioxolane (DLinKC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE), 16-O-monomethyl phosphatidyl ethanolamine, 16-O-dimethyl phosphatidyl ethanolamine, 18-1-trans phosphatidyl ethanolamine, 1-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), and N,N-dimethyl-2,3-dioleyloxy)propylamine (DODMA), and 1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLendMA).

6 - 8 . (canceled)

9 . The composition of claim 1 , wherein (i) a nucleic acid molecule, (ii) a small organic molecule, (iii) vaccine or (iv) antigen is present in the lipid nanoparticle.

10 . (canceled)

11 . The composition of claim 9 , wherein the nucleic acid molecule is present and is a siRNA, shRNA, plasmid, mRNA, miRNA or ncRNA.

12 . The composition of claim 1 , wherein the scFv is an anti-DEC-205 scFv, anti-Cd11c scFv, anti-33d1 scFv or anti-Clec9A (DNGR1) scFv.

13 - 26 . (canceled)

27 . A method of delivering a small molecule, a nucleic acid, a vaccine or an antigen to a cell expressing a cell-surface antigen, comprising contacting the cell with the composition of claim 1 , wherein the cell surface antigen is the antigen to which the scFv is directed, in an amount effective to deliver a small molecule, a nucleic acid, a vaccine or an antigen to a cell expressing a cell-surface antigen.

28 . A method of increasing the efficacy of a predetermined dose of a RNAi nucleic acid administered to a subject comprising delivering the RNAi nucleic acid to a cell expressing a cell-surface antigen, comprising contacting the cell with the composition of any of claim 1 , wherein the cell surface antigen is the antigen to which the scFv is directed, in an amount effective to deliver a RNAi nucleic acid to a cell expressing a cell-surface antigen and thereby increase the efficacy of the predetermined dose of a RNAi nucleic acid.

29 . The method of claim 27 , wherein the cell is a dendritic cell.

30 . The method of claim 27 , wherein the nucleic acid is delivered.

31 . (canceled)

32 . The method of claim 30 , wherein the nucleic acid is a siRNA, shRNA, plasmid, mRNA, miRNA or ncRNA.

33 . The method of claim 32 , wherein the nucleic acid is an immune-modulatory siRNA.

34 . A method of treating an immune system disorder in a subject comprising administering to the subject an amount of the composition of claim 1 , wherein the siRNA is an immunomodulatory siRNA or the small organic molecule is an immunomodulatory small organic molecule.

35 . The method of claim 34 , wherein the scFv is an anti-DEC-205 scFv.

36 . The method of claim 34 , wherein the siRNA is delivered.

37 . The method of claim 34 , wherein the immune system disorder is an autoimmune disorder.

38 . The method of claim 24 any of claims 34 - 37 , wherein the siRNA is directed against a human CD86, a human CD40 or a human CD80.

39 . The method of claim 34 , wherein the subject is a human.